RedShiftBio Sponsors MIBio 2019

MIBio 2019: Stability of Biopharmaceuticals – From molecular interactions to successful products

We are proud to be sponsoring the MIBio conference (Nov 13, 2019) at at Downing College, University of Cambridge. The event focuses on the application of molecular interaction-based discoveries in biopharmaceutical formulation to produce more effective, patient-friendly and safer therapeutic products.

The AQS3pro at MIBio 2019

RedShiftBio will be showcasing the microfluidic modulation spectroscopy (MMS)-based AQS3pro at MIBio 2019. The AQS3pro directly addresses the limitations of current secondary structure analysis technologies (FTIR, CD-UV etc). It provides unmatched dynamic range, increased sensitivity and multi sample walk away operation. See change in your proteins with The AQS3pro.

Biopharmaceutical Formulation

The biopharmaceutical product development landscape is rapidly changing. There are an increasing number of novel product modalities, including multi-specific antibodies, RNA based products, fusion proteins or various types of gene and cell therapies. Each of those products poses specific and different challenges that need to be addressed in the development process. In addition, stronger focus on patient-centric product strategies, increasingly more complex regulatory requirements and patent coverage further contributes to the challenge of developing robust drug products. MIBio 2019 will focus on these challenges as well as strategies to overcome them, particularly focusing on protein-protein interactions, formulation, drug product development and competitive product profiles. We look forward to seeing you there!